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Controlled trial of tamoxifen as a single adjuvant agent in the
management of early breast cancer
Analysis at Eight Years by 'Nolvadex'*
Adjuvant Trial Organisation.t
Summary At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant
tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients
receiving 20mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage,
grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and
suggests that more prolonged treatment might further improve results.
In the United States of America, adjuvant tamoxifen therapy
is now approved for the treatment of postmenopausal node
positive patients after the surgical excision of early breast
cancer. The National Institute of Health has recommended
this treatment for those patients who, in addition, have
oestrogen receptor positive primary tumours (Consensus
Conference, 1985).
The previous analyses of the Nolvadex Adjuvant Trial
Organisation (NATO) study (Nolvadex AdjuVant Trial
Organisation, 1983a, 1983b, 1985) had an important
influence on this recommendation. It is therefore of particu-
lar interest to review the more mature data from this trial.
This analysis presents the results at a median follow up of 66
months and in particular, examines the duration of treat-
ment effect and the relationship between prognostic variables
and the treatment effect.
Trial design and statistical methods
Full details are described in previous papers (Nolvadex
Adjuvant Trial Organisation, 1983a, 1983b, 1985). From
November 1977 to February 1981, 1,285 patients aged 75
years or less were randomised to receive either 10mg tamoxi-
fen (Nolvadex) twice daily for two years or no further
treatment following total mastectomy with axillary node
clearance or sampling. Node positive patients as determined
by node sampling received regional radiotherapy. Of the 642
patients randomised to tamoxifen and the 643 patients
receiving no further treatment, 76 and 75 patients respec-
tively were withdrawn from the analysis because they did not
satisfy the selection criteria, and two and one patients
respectively have no entry or follow up data.
This analysis is based on 564 tamoxifen treated and 567
control patients who satisfy the eligibility criteria and have
been followed for a median of five and a half years (range
8-94 months). A total of 525 primary tumour specimens
were assayed for ER content by modifications of the dextran
coated charcoal method in laboratories in Glasgow,
Manchester, Cardiff (Tenovus Institute), London (ICRF)
and Auckland, New Zealand. Quality control between labor-
atories was not part of this study but good agreement
between the British laboratories was subsequently shown in
the UK quality control study (Cowan & Leake 1984; King
et al., 1978).
Histology review and grading of tumours has been per-
formed by a single pathologist on 546 tumours.
*'Nolvadex' is a property of Imperial Chemical Industries plc.
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Statistical analysis was based on 'intention to treat policy'
with first event being either recurrence, contralateral breast
cancer or death without confirmed recurrence. The trial
census date for this analysis was 31 October 1985. 96% of
events occurring up until 28 February 1985 (minimum of 4
years follow up) have been subjected to external audit by
independent clinicians (Dr Helen Stewart, Edinburgh; Dr
Margaret Mackcracken, Leeds). Log rank analysis (Peto et
al., 1977) was performed to evaluate the difference between
treatment groups with respect to time to an event and
overall survival time. A multivariate regression method (Cox,
1972) was used to estimate the relative risks for events and
deaths in the two treatment groups and to detect whether the
treatment effect was the same in each of the prognostic
subgroups. Hazard rate ratio analysis was used to determine
the follow up period during which maximum contribution to
the overall treatment benefit was obtained. This analysis was
carried out by first calculating for each treatment group a
hazard rate which is simply the number of deaths or events
counted in a segment of time divided by the total patient-
months at risk in that segment. (Mathematically the hazard
rate corresponds with the slope of the survival or event curve
in each time segment (in this case 2 years) when the curve is
plotted on a logarithmic scale vertically). The log of the ratio
of hazard rates was then plotted against time with 95%
confidence limits. If the hazard rate in the tamoxifen treated
group is equivalent to that of the no treatment group the
hazard rate ratio will be 1 and the logarithm of this will be
zero. Hazard rate ratios falling below this zero line of
equivalence represent a treatment advantage; those falling
above the line represent an advantage in favour of the no
treatment group. The standard error is used to calculate
95% confidence limits for each hazard rate ratio. If the
confidence limits do not span the zero line of equivalence the
log ratio indicates a statistically significant (P<0.05) differ-
ence in hazard rates for the 2-year time segment in question.
Results
At a median follow up of 66 months there is a significant
reduction in the risk of suffering an event (X2 = 17.69,
P=0.0001). The relative risk for an event is 0.64 indicating a
36% reduction in risk for tamoxifen treated patients (95%
confidence limits 23% and 47%). There is also a significant
reduction in the risk of death from all causes (x2 =7.48,
P=0.0062). The reduction in relative risk is 29% for tamoxi-
fen treated patients (95% confidence limits 12% and 42%)
(Table I; Figures 1 & 2).
Table II shows the distribution of recurrences according to
site. The greatest reduction in favour of tamoxifen treated
patients appears to be in those patients developing a local
recurrence (24 tamoxifen vs. 50 control).
There was no evidence that tamoxifen increased the
number of deaths due to causes other than cancer (Table III)
(34 tamoxifen vs. 43 control).
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Table I Overall analysis of events and deaths
No. No. Relative risk + No. Relative risk +
Treatment patients events O/E 95% confidence limits deaths O/E 95% confidence limits
Tamoxifen 564 208 0.82 166 0.86
0.64 0.71a
(0.53,0.77) (0.58,0.88)
No treatment 567 274 1.20 210 1.14
P =0.0001.
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Figure 1 Life table for tamoxifen (all events).
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Figure 2 Life table for tamoxifen (all deaths).
The results of the log hazard ratio analysis for events and
deaths are shown in Figures 3 and 4. In the first two year
time segment (i.e., the adjuvant treatment period) the log
hazard ratio for events (Figure 3) is -0.6 with 95%
confidence limits between -0.3 and -0.85. There is there-
fore a beneficial treatment effect which is statistically signifi-
cant. Moving to the 24-48 months and 48-72 months time
segments, the treatment effects are smaller and no longer
statistically significant. In the fourth period the log ratio of
hazard rates is greater than zero, but patient numbers are
small and the confidence limits which span zero are wide. A
similar pattern may be seen for the survival data (Figure 4).
A statistically significant treatment benefit is seen between
months 24 and 48. This is reduced and is not statistically
significant between months 48 and 72. The log hazard rate
ratio is greater than 0 between 72 and 96 months, again this
does not represent a rebound phenomenon with an acceler-
ated death rate in the treated group due to the small
numbers of patients at risk and the width of the confidence
limits which span zero.
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Table II Distribution of sites of first recurrence within treatment
groups
Tamoxifen No treatment
Site offirst recurrence n(%) n(%)
Local 24 (14.6) 50 (22.3)
Regional 15 (9.1) 26 (11.6)
Local/regional 0 (0) 6 (2.7)
New primary 11(67) 9 (4.0)
New primary/local 1 (0.6) 0 (0)
Distant 113 (69) 133 (59)
Total 164 224
Table III Cause of death within treatment groups
Tamoxifen No treatment
Cause of death n(%) n(%)
Due to breast cancer 123 (74) 146 (69.5)
Not due to breast cancer but
breast cancer present 6 (3.6) 18 (8.6)
Not due to breast cancer 34 (20.5) 43 (20.5)
Not known 3 (1.8) 3 (1.4)
Total 166 210
No. of patients at risk
Tamoxifen 564 519 470 433 387 250 110 18
No treatment 567 499 414 367 332 207 91 13
Figure 3 Log ratio of hazard rates (with 95% confidence
limits).
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The population was divided according to menopausal and
nodal status and observed to expected ratios calculated for
tamoxifen and no treatment groups (Table IV). The multi-
variate regression analysis did not detect any significant
variation in treatment effect between subgroups. The
observed to expected ratios favour tamoxifen treatment
equally in each subgroup.
The ER status of the primary tumour was a significant
prognostic variable. At cut-off values of 5 and 30fmolmg-1
cytosol protein, ER positive patients had a significantly
better prognosis for both events and deaths (Table V).
The population was divided according to ER status and
observed to expected ratios calculated for each treatment
group (stratified for the effects of menopausal and nodal
status). Observed to expected ratios favoured the tamoxifen
treated patients in each subgroup. The multivariate regres-
sion analysis again did not detect any significant variation in
treatment effect between ER subgroups (Table VI).
The histological grade of the primary tumour is a prog-
nostic variable (Table VII) and is associated with the ER
status at cut off values of 5fmol and 30fmol (Table VIII).
The greatest benefit for treatment is in grade I and II
tumours compared to grade III tumours (Table IX).
Discussion
At a maximum follow up of 8 years adjuvant tamoxifen
therapy prescribed for two years after surgery continues to
be associated with a significant reduction in the number of
events and deaths. This benefit is independent of meno-
pausal, nodal and ER status. There is no evidence of a
rebound increase in number of events or deaths on with-
drawal of treatment. However, the hazard ratio is greater
than zero after 6 years. This is not significant and a final
conclusion about this important consideration must await
further follow up.
With regard to the hazard ratios, adjuvant tamoxifen
seems to have an immediate effect on events but a delayed
effect on survival. This difference in effect suggests either
that prolonged treatment is necessary to improve mortality
or that the greatest effect of treatment occurs in patients
with a life expectancy of two to four years after the
operation. The latter interpretation seems unlikely in view of
the lack of interaction between the treatment effect and
prognostic variables. If the former is true then prolongation
of treatment might provide additional improvements in
survival. This concept is supported by studies of MCF-7 cells
Table IV Effect of treatment within menopausal and nodal subgroups
Group Number No. events O/E No. deaths O/E
Premenopausal node positive
Tamoxifen 72 34 0.80 28 0.83
No treatment 57 36 1.31 30 1.24
Postmenopausal node negative
Tamoxifen 300 80 0.84 55 0.83
No treatment 305 107 1.17 77 1.17
Postmenopausal node positive
Tamoxifen 181 87 0.77 77 0.85
No treatment 190 123 1.26 99 1.16
Regression analysis showed no significant interaction between subgroups and
tamoxifen effect.
Table V Effect of oestrogen receptor status on events and deaths
(Stratified for the effect of nodes, menopause and treatment)
ER value Number No. events O/E No. deaths O/E
< 5 fmol 189
>=Sfmol 324
x2
P value
<30fmol 260
> =30fmol 253
x2
P value
82 1.16
133 0.92
2.99
0.084
114 1.15
101 0.87
4.30
0.038
70 1.27
103 0.87
6.32
0.012
96 1.23
77 0.81
7.68
0.006
Table VI Effect of treatment within oestrogen receptor subgroups
(Stratified for the effects of nodes and menopause)
Group Number No. Events O/E No. deaths O/E
ER<5fmol
Tamoxifen 105 33 0.65 28 0.67
No treatment 84 49 1.55 42 1.48
ER> =5fmol
Tamoxifen 152 53 0.77 42 0.82
No treatment 172 80 1.25 61 1.18
ER<30fmol
Tamoxifen 138 47 0.74 40 0.77
No treatment 122 67 1.32 56 1.27
ER>30fmol
Tamoxifen 119 39 0.71 30 0.75
No treatment 134 62 1.34 47 1.27
Regression analysis showed no significant interaction between
subgroups and tamoxifen effect.
Table VII Effect of histological grade on events and deaths (Stratified
for the effects of nodes and menopause)
Group Number No. events O/E No. deaths O/E
Grade I
Grade II
Grade III
188
273
78
x2
P value
68
121
54
0.78
0.96
1.79
23.81
0.0001
49
96
50
0.71
0.95
2.01
32.31
0.0001
Table VIII Relationship between oestrogen
receptor status and histological grade
%ER+ VE at
Group 5fmol 30fmol Median ER
Grade I 68 58 51
Grade II 72 55 44
Grade III 58 38 10
Table IX Effect of treatment within subgroups divided according
to histological grade (Stratified for the effect of nodes and
menopause)
Group Number No. events O/E No. deaths O/E
Grade I
Tamoxifen 101 22 0.84 22 0.84
No treatment 87 27 1.19 27 1.19
Grade II
Tamoxifen 139 39 0.76 39 0.76
No treatment 134 57 1.28 57 1.28
Grade III
Tamoxifen 38 25 0.99 25 0.99
No treatment 40 25 1.01 25 1.01NATO TRIAL - 8-YEAR ANALYSIS 611
which are inhibited in their growth by a reduction of the
growth fraction. Non-cycling cells (Go phase) may survive in
the tumour for a long period of time (Lykkesfeldt et al.,
1984).
In advanced breast cancer ER, histological grade and
disease free interval are dependent variables which predict
responsiveness to endocrine therapy. In this trial none of
these variables predicted the response to adjuvant therapy.
There are two criticisms which must be countered before
discussing some possible reasons for these differences in the
response of advanced and early disease. Firstly, inadequate
quality control in the assay of ER: this is unlikely because
this trial concurred with many other studies showing that
ER is a prognostic variable and is associated with histologi-
cal grade. Secondly, lack of statistical power: clearly the
power to detect a significant treatment effect within sub-
groups is much less than for the study as a whole, however
the observed to expected ratios are remarkably consistent
(with the possible exception of tumours of grade III malig-
nancy) and in favour of tamoxifen treatment in each sub-
group investigated. To summarize then, although ER status
and histological grade were found to be prognostic indi-
cators for the groups as a whole, therefore acting as an
internal check on validity of the methods, no subgroup
based on these variables was associated with a qualitative
advantage for adjuvant tamoxifen treatment.
The absence of a correlation between ER status and
treatment effects suggests that tamoxifen may have anti-
tumour actions independent of the oestrogen receptor. The
studies of Sutherland et al. (1986) on human breast cancer
cells in tissue culture have clearly demonstrated two distinct
mechanisms of growth inhibition. In addition to ER-
mediated, oestrogen-reversible growth inhibition, high con-
centrations of tamoxifen produce oestrogen-irreversible
growth inhibition. The latter effect is distinguished from a
non-specific cytoxic mechanism by its cell cycle specificity
(Sutherland et al., 1983). Both growth inhibitory mechanisms
are confined to a precise time in the G1 phase of the cell
cycle and may converge on common pathways which control
cell division. Several candidate mechanisms for such effects
have emerged recently which may be the target for tamoxifen
action. These include inhibition of protein kinase C (O'Brien
et al., 1986) and calmodulin action (Lam, 1984). Calmodulin
plays an important role in the control of cell cycle progres-
sion and may also be involved in ER activation.
It is clear from immunocytochemical studies using a
monoclonal antibody to detect ER in human breast tumours
that expression of ER is highly heterogeneous (Marchetti et
al., 1985). In addition Knabbe et al. (1987) have demon-
strated a mechanism by which antioestrogen effects on ER
positive cells may influence the growth of ER negative cells.
Tamoxifen stimulates the secretion of TGF-,B by the ER
positive human breast cancer cell line MCF7. This peptide
inhibits the growth of breast cancer cells irespective of their
ER status. Thus tamoxifen stimulated TGF-,B may act in an
autocrine and paracrine manner to inhibit breast tumour
growth and with such a mechanism it would be possible for
a few ER+ cells to inhibit the growth of a micrometastasis
dominated by ER-cells.
Finally, are we in a position to make therapeutic recom-
mendations? This trial is not the only one to show a
significant benefit from adjuvant tamoxifen and the result
can be judged 'typical' in the light of a world overview of
tamoxifen trials (Peto, personal comm; Anonymous, 1984).
The drug itself is virtually free from significant side effects
up to 8 years of follow up and the life table plot describes
benefit for the group in terms of a relative risk reduction of
about 30%. As there is no apparent interaction between
treatment and prognostic subgroups, the greater the risk of
relapse, the greater the absolute risk reduction following
treatment with tamoxifen (e.g. 30% risk of relapse over 5
years, absolute risk reduction with tamoxifen=9%; 10% risk
of relapse over 5 years, absolute risk reduction with tamoxi-
fen=3%). Clinicians can now make rational decisions about
whether or not to prescribe tamoxifen which are likely to
differ from the NIH consensus recommendation which only
recommended the drug for postmenopausal women with
ER+tumours.
Our final plea is to clinicians who still have an open mind
on the subject to enter patients into trials comparing 2 years
with 5 years of adjuvant therapy or trials investigating the
role of radiotherapy amongst patients receiving adjuvant
tamoxifen therapy as a standard.
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